Protecting the heart during treatment for acute myeloid leukemia

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the potential cardioprotective effects of beta blockers and ACE inhibitors in patients undergoing treatment for acute myeloid leukemia (AML) with the drug daunorubicin. Participants will be randomly assigned to receive either these preventive medications or standard care without them. The study aims to assess the frequency of heart damage caused by anthracycline chemotherapy and will monitor heart function through electrocardiograms, echocardiograms, and blood tests. Additionally, quality of life will be evaluated through questionnaires at various time points during the study.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Signed informed consent obtained prior to conducting any study-specific screening procedures.
2. Willing and able to understand the nature of this study and to comply with both the study as well as follow-up procedures for the duration of the study.
3. Age ≥ 18 years old with newly-diagnosed Acute Myeloid Leukemia (AML)
4. ECOG performance status must be ≤ 2
5. Planning to receive initial induction therapy containing an anthracycline for AML. Participants may have started initial induction therapy if anthracycline has not yet been administered.
6. Adequate organ function as evidenced by the following laboratory findings:

   1. Total bilirubin ≤ 1.5 x upper limit of normal (ULN) or \< 3 x ULN for patients with Gilbert's Syndrome
   2. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x ULN
   3. Creatinine clearance \> 60 mL/min
7. Ability to take oral medication and a willingness to adhere to the beta blocker and lisinopril regimen
8. Echocardiogram demonstrating an ejection fraction ≥ 50% prior to the initiation of induction chemotherapy
9. For females of reproductive potential and males: Agree to abstain from sexual activity or use reliable contraception while undergoing treatment with chemotherapy and/or ACE inhibitors due to the risk of teratogenicity to the fetus.

Exclusion Criteria:

1. Ongoing use of any beta blocker, ACEi, or angiotensin II receptor agonist (ARB) at the time of pre-enrollment screening.
2. Uncontrolled, intercurrent illnesses including but not limited to symptomatic unstable angina pectoris, cardiac arrhythmias not well controlled with medications, myocardial infarction in the 6 months preceding registration or psychiatric illness/social situations that would limit compliance with study requirements as determined by the study personnel, all at the discretion of the treating oncologist.
3. Patient receiving concurrent investigational agents, or those who have received an investigational agent within one week of registration.

Exception - Participants may receive concurrent investigational agents, or have done so within one week of registration if:

* The side effects of the drug are well studied and well known AND
* The drug is not known to be cardioprotective or cardiotoxic

  4\. Females who are pregnant or lactating.

  5\. Life-threatening illnesses other than AML, uncontrolled medical conditions or organ system dysfunction that, in the investigator's opinion, could compromise the patient's safety or study outcomes.

  6\. Active, untreated and/or severe infections as determined by the treating oncologist.

  7\. History of hematopoietic stem cell transplant (HSCT) with active graft vs host disease, immunosuppression other than low-dose prednisone (≤ 5mg) or calcineurin inhibitors within the four weeks preceding registration

  8 Moderate or severe mitral or aortic valve disease, as determined by echocardiography

  9\. Congestive heart failure as clinically diagnosed by treating oncologist at the time of presentation for induction chemotherapy, or documented diagnosed by a previous physician.

  10\. History of (repaired or unrepaired) congenital heart disease that precludes recommendation for or administration of additional anthracyclines

  11\. Significant liver disease, including cirrhosis or history of transplant or hepatorenal syndrome)

  12\. Bradycardia (defined as baseline resting heart rate ≤ 60 beats per minute) or third degree atrioventricular heart block at presentation for induction chemotherapy.

  13\. Baseline resting systolic blood pressure \< 95mmHg at presentation for induction chemotherapy.

  14\. Documented allergy to beta blockers or ACE inhibitors.

Where it's running

• University of Virginia
  Charlottesville, Virginia, United States Recruiting

Study contacts

• Principal investigator: Michael Keng, MD — Uva
• Study coordinator: Cory Caldwell, RN
• Email: CJC2P@uvahealth.org
• Phone: 434-297-4182

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• CRD3874-SI in People with Leukemia

  A small early-stage study tests CRD3874-SI to see if it is safe for adults with relapsed or refractory acute myeloid leukemia.

  Recruiting at 7 sites Phase 1 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07661095

• Reduced-intensity donor stem cell transplant with treosulfan/fludarabine and post-transplant cyclophosphamide for leukemia and MDS

  This trial tests a lower-intensity donor stem cell transplant using treosulfan plus fludarabine with post-transplant cyclophosphamide to try to reduce toxicity and prevent graft-versus-host disease in people aged 2–75 with acute leukemias or myelodysplastic syndromes.

  Recruiting Phase 2 Masonic Cancer Center, University of Minnesota · Minneapolis, Minnesota · NCT07493538

• New treatment for patients with relapsed acute myeloid leukemia

  This study is testing a new treatment called CER-1236 to see if it can help people with relapsed acute myeloid leukemia feel better and improve their chances of recovery.

  Recruiting at 5 sites Phase 1 CERo Therapeutics Holdings, Inc. · Sacramento, California and 4 other locations · NCT06834282

• CAR-T cell therapy targeting CD33 and CD123 for treating acute myeloid leukemia

  This study is testing a new CAR-T cell therapy that targets specific markers in the blood to see if it can help people with acute myeloid leukemia who haven't responded to other treatments.

  Recruiting Phase 1/2 Essen Biotech · Beijing, Beijing Municipality · NCT06420063

• Combination treatment for newly diagnosed acute myeloid leukemia

  This study is testing a new combination treatment for adults with newly diagnosed acute myeloid leukemia who can't have standard chemotherapy to see if it can help them safely and effectively.

  Recruiting Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality · NCT06386302

• Combining revumenib with standard chemotherapy and targeted therapy for acute myeloid leukemia

  This study is testing a new treatment combining revumenib with standard chemotherapy and another targeted therapy to see if it helps newly diagnosed patients with a specific type of acute myeloid leukemia.

  Recruiting at 2 sites Phase 1 Dana-Farber Cancer Institute · New Haven, Connecticut and 1 other locations · NCT06313437

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.